Related Experiment Video

Updated: Jul 16, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Emerging drugs for the treatment of soft tissue sarcomas

Philippe A Cassier1, Armelle Dufresne, Jérôme Fayette

  • 1Unité de Jour Oncologie Médicale Multidisciplinaire, Hopital Edouard Herriot, Lyon, France.

Expert Opinion on Emerging Drugs
|March 16, 2007
PubMed

Insights

Soft tissue sarcomas, rare cancers, are increasingly understood at a molecular level. This understanding is driving targeted therapies, like kinase inhibitors, for advanced disease treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Soft tissue sarcomas are rare, heterogeneous cancers originating from mesenchymal cells.
  • Advances in understanding sarcoma biology have identified distinct molecular subtypes.
  • This knowledge facilitates the development of targeted therapies.

Purpose of the Study:

  • To review current treatment strategies for advanced soft tissue sarcomas.
  • To discuss emerging therapeutic compounds for soft tissue sarcoma patients.

Main Methods:

  • Review of scientific literature on soft tissue sarcoma biology and treatment.
  • Analysis of targeted therapies, including kinase inhibitors.
  • Summary of ongoing research and development of new compounds.

Main Results:

  • Identification of specific molecular alterations, such as KIT mutations in gastrointestinal stromal tumors (GIST).
  • Development of targeted drugs like imatinib and sunitinib, demonstrating successful targeted therapy.
  • Establishment of a paradigm for treating solid tumors by inhibiting oncogenic drivers.

Conclusions:

  • Targeted therapies based on molecular alterations represent a paradigm shift in soft tissue sarcoma treatment.
  • Ongoing research is crucial for developing novel compounds to improve outcomes for advanced soft tissue sarcoma.
  • Personalized medicine approaches are key to managing this rare cancer group.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...